Bromfenac
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Bromfenac
Description :
Bromfenac is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac can be used in ocular inflammation research[1].UNSPSC :
12352005Hazard Statement :
H302-H315-H319-H335Target :
COXType :
Reference compoundRelated Pathways :
Immunology/InflammationApplications :
COVID-19-immunoregulationField of Research :
Infection; Inflammation/ImmunologyAssay Protocol :
https://www.medchemexpress.com/bromfenac.htmlSolubility :
10 mM in DMSOSmiles :
O=C(O)CC1=CC=CC(C(C2=CC=C(Br)C=C2)=O)=C1NMolecular Formula :
C15H12BrNO3Molecular Weight :
334.16Precautions :
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501References & Citations :
[1]Tetsuo Kida, et al. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. PLoS One. 2014 May 5;9 (5) :e96481.|[2]Xiaobo Zhang, et al. Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification. Bioact Mater. 2021 Jul 23;9:343-357.|[3]Nolan JC, et, al. The topical anti-inflammatory and analgesic properties of bromfenac in rodents. Agents Actions. 1988 Aug; 25 (1-2) : 77-85.|[4]Kaevalin Lekhanont, et al. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. J Ocul Pharmacol Ther. 2007 Feb;23 (1) :27-34.Shipping Conditions :
Room temperatureScientific Category :
Reference compound1Clinical Information :
LaunchedIsoform :
COX-1; COX-2CAS Number :
[91714-94-2]

